» Articles » PMID: 30798327

ADAR1 P110 Enhances Adhesion of Tumor Cells to Extracellular Matrix in Hepatocellular Carcinoma Via Up-Regulating ITGA2 Expression

Overview
Journal Med Sci Monit
Date 2019 Feb 25
PMID 30798327
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND Intrahepatic and distant metastases could be the major cause of treatment failure in hepatocellular carcinoma (HCC). The deep mechanism of HCC metastasis is closely related to the interaction between integrins and extracellular matrix (ECM) in tumor microenvironment. MATERIAL AND METHODS In vitro cell adhesion assay was performed to determine the capability of adhering to ECM elements of HCC cells. To modulate the expression status of ADAR1 p110 in tumor cells, lentivirus system was applied. Meanwhile, patients' HCC samples and orthotopic xenograft mouse model were used for verifying our in vitro data. RESULTS ADAR1 p110 could strongly enhance the adhesion of HCC tumor cells to ECM, which was usually regarded as the initiation of tumor invasion. Such phenotype was caused due to up-regulation of ITGA2 both in mRNA and protein level. Moreover, specimen collected from HCC patients revealed a positive correlation between ADAR1 and ITGA2. Finally, ADAR1 p110 promoted HCC metastasis was verified when we applied orthotopic xenograft mouse model. CONCLUSIONS ADAR1 could enhance HCC metastasis by promoting tumor cells adhering to ECM via increasing ITGA2 expression. This phenomenon could provide novel information to better understanding the mechanism of HCC metastasis procedure.

Citing Articles

Emerging roles of CircRNA-miRNA networks in cancer development and therapeutic response.

Hashemi M, Khosroshahi E, Daneii P, Hassanpoor A, Eslami M, Koohpar Z Noncoding RNA Res. 2024; 10:98-115.

PMID: 39351450 PMC: 11440256. DOI: 10.1016/j.ncrna.2024.09.006.


Suppression of A-to-I RNA-editing enzyme ADAR1 sensitizes hepatocellular carcinoma cells to oxidative stress through regulating Keap1/Nrf2 pathway.

Wang H, Wei X, Liu L, Zhang J, Li H Exp Hematol Oncol. 2024; 13(1):30.

PMID: 38468359 PMC: 10929210. DOI: 10.1186/s40164-024-00494-7.


Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics.

Janin M, Davalos V, Esteller M Cancer Metastasis Rev. 2023; 42(4):1071-1112.

PMID: 37369946 PMC: 10713773. DOI: 10.1007/s10555-023-10120-3.


Biological roles of A-to-I editing: implications in innate immunity, cell death, and cancer immunotherapy.

Yuan J, Xu L, Bao H, Wang J, Zhao Y, Chen S J Exp Clin Cancer Res. 2023; 42(1):149.

PMID: 37328893 PMC: 10276482. DOI: 10.1186/s13046-023-02727-9.


RNA Editing Enzyme ADAR1 Suppresses the Mobility of Cancer Cells via ARPIN.

Park M, Jeong E, Lee E, Choi H, Moon B, Kang K Mol Cells. 2023; 46(6):351-359.

PMID: 36921992 PMC: 10258462. DOI: 10.14348/molcells.2023.2174.


References
1.
Liotta L, Kohn E . The microenvironment of the tumour-host interface. Nature. 2001; 411(6835):375-9. DOI: 10.1038/35077241. View

2.
Dong J, Wang R, Ren G, Li X, Wang J, Sun Y . HMGA2-FOXL2 Axis Regulates Metastases and Epithelial-to-Mesenchymal Transition of Chemoresistant Gastric Cancer. Clin Cancer Res. 2017; 23(13):3461-3473. DOI: 10.1158/1078-0432.CCR-16-2180. View

3.
Shen L, Liu L, Yang Z, Jiang N . Identification of genes and signaling pathways associated with squamous cell carcinoma by bioinformatics analysis. Oncol Lett. 2016; 11(2):1382-1390. PMC: 4734263. DOI: 10.3892/ol.2015.4051. View

4.
Marastoni S, Ligresti G, Lorenzon E, Colombatti A, Mongiat M . Extracellular matrix: a matter of life and death. Connect Tissue Res. 2008; 49(3):203-6. DOI: 10.1080/03008200802143190. View

5.
. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4):908-43. DOI: 10.1016/j.jhep.2011.12.001. View